GalChimia is part of the consortium selected by the H2020 EU for grant funding of €7.9 million

GalChimia is part of the consortium selected by the H2020 EU for grant funding of €7.9 million.
Santiago, Spain, 30 March 2015 – GalChimia is pleased to announce that it is taking part in the consortium NanoFacturing, awarded with a project grant of €7.9 million from Horizon 2020, the European Union research and innovation program backed by the European Commission. The project is led by Midatech Pharma España and the grant will fund the manufacturing scale-up of clinical-grade nanopharmaceuticals for use in clinical trials and in preparation for commercial production.

The project is entitled “NanoFacturing – The Development of Medium- and Large-Scale Sustainable Manufacturing Process Platforms for Clinically Compliant Solid Core Nanopharmaceuticals.” GalChimia is specifically involved in the synthesis of the ligands used to bind the nanoparticle to another chemical or biological molecules. For the GMP synthesis of the ligands GalChimia is collaborating with its partner Applus+ Laboratories. GalChimia will receive just over €0.5 million in funding.

In addition to GalChimia and Applus+ Laboratories, the NanoFacturing consortium includes: Midatech Pharma (Spain and UK); Centre for Process Innovation Limited (UK); Prochimia Surfaces SP.Z.O.O (Poland); University College Dublin, National University of Ireland (Ireland); IFOM, Fondazione Istituto FIRC di Oncologia Molecolare (Italy); and Ecole Polytechnique Federale de Lausanne (Switzerland).

Further information on NanoFacturing: It is a scalable manufacturing platform to support the wide range of nanopharmaceutical products being developed in Europe, including Midatech’s own GNP-based drug conjugate candidates. It aims to address the small and medium scale needs of early phase clinical trials and niche applications, whilst also supporting the development of clinically compliant, sustainable large scale manufacturing processes capable of taking these products through Phase III trials into commercial manufacture and supply into large potential markets.

For any additional information, please contact Ms. Julie Masse